Maplight Therapeutics, Inc. $MPLT Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lessened its stake in Maplight Therapeutics, Inc. (NASDAQ:MPLT) by 31.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,016 shares of the company’s stock after selling 65,478 shares during the period. Lazard Asset Management LLC owned 0.33% of Maplight Therapeutics worth $2,887,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of MPLT. Strs Ohio bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $53,000. Blue Owl Capital Holdings LP acquired a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $5,745,000. Geode Capital Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter worth approximately $6,835,000. Seven Grand Managers LLC acquired a new stake in Maplight Therapeutics in the fourth quarter worth approximately $1,756,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Maplight Therapeutics in the fourth quarter worth approximately $34,026,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on MPLT. Canaccord Genuity Group lowered their price target on Maplight Therapeutics from $43.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus raised their target price on Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 1st. TD Cowen initiated coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating on the stock. Lifesci Capital upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Finally, HC Wainwright cut their price target on shares of Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Four investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Buy” and an average price target of $34.42.

Insider Buying and Selling

In other news, Director Troy Cox bought 15,620 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were acquired at an average cost of $9.52 per share, with a total value of $148,702.40. Following the completion of the transaction, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Erin Pennock Foff sold 24,052 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $691,735.52. Following the sale, the insider owned 350,497 shares in the company, valued at $10,080,293.72. This represents a 6.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 379,987 shares of company stock worth $10,644,411. Company insiders own 3.80% of the company’s stock.

Maplight Therapeutics Stock Performance

NASDAQ MPLT opened at $13.02 on Friday. Maplight Therapeutics, Inc. has a 1 year low of $9.10 and a 1 year high of $40.43. The business’s fifty day moving average is $30.66 and its two-hundred day moving average is $24.88. The stock has a market capitalization of $554.89 million and a P/E ratio of -0.32.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, research analysts forecast that Maplight Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.